ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has a robust pipeline ...

Arrowhead Pharmaceuticals Inc (ARWR) reports robust earnings, strategic partnerships, and pipeline progress, while navigating ...

Learn more about whether Arrowhead Pharmaceuticals, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Q2 2025 Earnings Call Transcript May 12, 2025 Arrowhead Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $2 ...

ARROWHEAD PHARMACEUTICALS ($ARWR) posted quarterly earnings results on Monday, May 12th. The company reported earnings of $2.75 per share, beating estimates of -$0.20 ...

--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (ARWR) today announced financial results for its fiscal 2025 second quarter ended March 31, 2025. The Company is hosting a conference call ...

The Pasadena, Calif., biotechnology company, which uses RNA interference to develop treatments, said Monday it recorded a profit of $370.4 million, or $2.75 a share, during the fiscal second quarter, ...

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery ...

Conference Call and Webcast Today, May 12, 2025, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 second quarter ended March 31 ...

Q2 2025 Earnings Conference Call May 12, 2025 4:30 PM ET. Company Participants. Vincent Anzalone - Vice President of Investor Relatio ...